

Amendment
U.S. Appl. No.: **10/595,635**
Attorney Docket No. **LAV0313158**

REMARKS

By the present amendment, the specification has been amended to insert section subtitles and to correct minor defects, and the abstract has been amended to avoid legal phraseology and to be reduced to 114 words.

Claim 1 has been amended to replace “the or each post-injection” by “post-injections” and to add “during this stage of idling” for legibility without affecting the claim scope.

Claims 8-11 corresponding to claims 3-4 have been added to reintroduce the multiple dependencies of original claims 3-4.

Further, new method claims 12-22 corresponding to claims 1-11 have been added. The present application is a national stage of a PCT application, so “unity of invention” rules apply. Accordingly, it is submitted that system and method claims should be examined together in this application.

Claims 1-22 are pending in the present application. Claims 1 and 12 are the only independent claims.

I. **Objection to the specification**

In the Office Action, the abstract is objected to as including legal phraseology “means,” and the specification is objected to as missing section subtitles.

The abstract has been amended to avoid legal phraseology and to be reduced to 114 words as follows:

~~This system System in which the depollution means (1) are device is associated with an oxidation catalyst forming means (2), and the engine (4) is associated with a common rail means (7) for feeding it with fuel and adapted to implement a regeneration strategy using at~~

Amendment

U.S. Appl. No.: **10/595,635**

Attorney Docket No. **LAV0313158**

least one post-injection of fuel into the cylinders, is characterized in that it includes means (8) for detecting In the system, a request for regeneration (req.RG) can be detected, means (9) for detecting that whether the engine is in a stage of idling can be detected, means (11) for acquiring a temperature downstream from the catalyst forming means can be acquired, means (8) for determining a maximum duration for post-injection application during the stage of idling can be determined on the basis of said temperature, and means (7, 8) for progressively reducing the post-injection can be progressively reduced as soon as the duration of use has reached the maximum duration.

Further, the specification has been amended to insert section subtitles.

In view of the above, it is submitted that the objections should be withdrawn.

II. Objection to the claims

In the Office Action, claims 3-4 are objected to. It is alleged in the Office Action that “comprise” should be “comprised.”

Claims 3-4 have been amended as suggested in the Office Action. Accordingly, it is submitted that the objection should be withdrawn.

III. Art rejections

In the Office Action, claims 1-3 are rejected under 35 U.S.C. 102(e) as anticipated by US 6,951,100 to Kuboshima (“Kuboshima”).

Further, in the Office Action, claim 4 is rejected under 35 U.S.C. 103(a) as obvious over Kuboshima in view of US 2002/0007629 to Asanuma et al. (“Asanuma”), claims 5-6 are rejected under 35 U.S.C. 103(a) as obvious over Kubshima in view of US 4,655,037 to Rao (“Rao”), and claim 7 is rejected under 35 U.S.C. 103(a) as obvious over Kuboshima in view of an official notice.

Amendment
U.S. Appl. No.: **10/595,635**
Attorney Docket No. **LAV0313158**

Reconsideration and withdrawal of the rejection is respectfully requested.

Kuboshima is a U.S. patent issued on October 4, 2005 from an application filed on November 28, 2003 and published on July 8, 2004. Since the present application is a national stage of PCT/FR2004/002514 filed October 5, 2004, the publication date of the US application publication to Kuboshima and the issue date of the US patent to Kuboshima are not more than one year before the PCT filing date of the present application. Further, the earliest effective date of Kuboshima is the filing date of the US application on November 28, 2003, which is later than the priority date claimed in the present application (French Appl. No. 0313158 filed November 7, 2003).

A certified English translation of the French application is submitted with this paper. The text of the priority French application is substantially identical to the text of the present application. Thus, Kuboshima is not available against the present application.

In view of the above, it is submitted that the rejections should be withdrawn.

In conclusion, the invention as presently claimed is patentable. It is believed that the claims are in allowable condition and a notice to that effect is earnestly requested.

In the event there is, in the Examiner's opinion, any outstanding issue and such issue may be resolved by means of a telephone interview, the Examiner is respectfully requested to contact the undersigned attorney at the telephone number listed below.

In the event this paper is not considered to be timely filed, the Applicants hereby petition for an appropriate extension of the response period. Please charge the fee for such extension and any other fees which may be required to our Deposit Account No. 502759.

Amendment
U.S. Appl. No.: **10/595,635**
Attorney Docket No. **LAV0313158**

Respectfully submitted,

/nicolas seckel/

Nicolas E. Seckel
Attorney for Applicants
Registration No. 44,373

Nicolas E. Seckel
Patent Attorney
1250 Connecticut Avenue, NW Suite 700
Washington, DC 20036
Tel: 202-669-5169
Fax: 202-822-1257
Customer No.: 29980
NES/rep